The evolution of cell and gene therapy is reshaping drug discovery, providing new hope for rare diseases and cancer through innovative gene editing approaches.

OXB announces that its proprietary lentiviral vector manufacturing technology will be used in Boehringer Ingelheim’s newly initiated LENTICLAIR ...

Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC) 1 and OXB, 1 today announce the start of LENTICLAIR TM 1, a Phase I/II trial of BI 3720931, a novel, first-in-class, ...

The strata retail market remained muted in the second half of 2024, with a slight decline of 1.3% in total sales value to S$214.8 million from S$217.5 million i ...

According to a Cushman and Wakefield report, for the whole year 2024, Ho Chi Minh City had 117,500 sqm of new supply from five Grade A buildings, three of which ...